Last $163.13 USD
Change Today +1.31 / 0.81%
Volume 3.1M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$158.78
Previous Close
$161.82
Day High
$163.43
Day Low
$158.52
52 Week High
06/30/14 - $174.49
52 Week Low
09/11/13 - $86.95
Market Cap
50.2B
Average Volume 10 Days
2.7M
EPS TTM
$5.14
Shares Outstanding
307.6M
EX-Date
08/13/14
P/E TM
31.8x
Dividend
$0.20
Dividend Yield
0.12%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,700 Employees
Last Reported Date: 08/5/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan, Inc. Announces Management Changes

Allergan Inc. announced that Jim Hindman has been named Executive Vice President, Finance and Business Development, Chief Financial Officer, effective immediately. Mr. Hindman succeeds Jeff Edwards, who after 21 years of service to the company, including nine years in the Chief Financial Officer role, has decided to step down from the position due to family commitments. Mr. Edwards will remain employed by the company in a non-executive officer capacity to facilitate a smooth transition. Mr. Hindman joined the company in 1984 and has served as Senior Vice President, Treasury, Risk and Investor Relations since 2002. Prior to that, he served in a variety of finance positions, including Senior Vice President, Finance and Controller, Assistant Corporate Controller and Vice President, Financial Planning and Analysis. Mr. Hindman also serves as President of The Allergan Foundation. Before joining the company, Mr. Hindman worked at Deloitte, Haskins and Sells.

Allergan Announces OZURDEX(R) Receives European Positive Opinion for the Treatment of Diabetic Macular Edema

Allergan Inc. announced that the European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX(R) (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. The CHMP is the scientific committee of the European Medicines Agency (EMA) that recommends medicines for Marketing Authorization across the 28 member states of the European Union. The final decision from the European Commission is expected within a few months. DME is a condition that affects approximately 7% of patients with diabetes and is one of the main causes of sight loss in patients with diabetes. The OZURDEX(R) implant uses the proprietary and innovative NOVADUR(R) solid polymer delivery system -- a biodegradable implant that releases medicine over an extended period of time -- to suppress inflammation, which plays a key role in the development of DME. OZURDEX(R) (dexamethasone 700 mcg intravitreal implant in applicator) is already available throughout the European Union as a treatment licensed for macular edema in patients with retinal vein occlusion (RVO) and for inflammation of the posterior segment of the eye characterized as non-infectious uveitis.

Valeant it has Filed a Complaint with Securities Regulators in Quebec and the U.S

Valeant said on July 21, 2014 it has filed a complaint with securities regulators in Quebec and the U.S. over allegedly unfair tactics by Allergan Inc. Valeant said it has contacted both the Autorité des marchés financiers and the U.S. Securities and Exchange Commission regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information. Valeant says Allergan falsely stated last Friday in an SEC filing that Valeant's Bausch + Lomb pharmaceutical sales were stagnant or declining, when in fact they grew about 6% in the second quarter. The U.S. prescription pharmaceutical business grew 17% over the year-earlier period, with the lion's share of that growth due to volume increases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $163.13 USD +1.31

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $223.36 USD +0.28
Astellas Pharma Inc ¥1,518 JPY +22.50
Beiersdorf AG €66.73 EUR -0.34
Regeneron Pharmaceuticals Inc $345.28 USD -1.51
Shire PLC 4,913 GBp +19.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 37.1x
Price/Sales 7.1x
Price/Book 7.1x
Price/Cash Flow 34.4x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.